Neuren Australian Clinical Trial
Welcome to Neuren Pharmaceuticals (www.neurenpharma.com; ASX:NEU). Neuren is a Melbourne-based company at the forefront of efforts to develop effective treatments for rare, paediatric neurodevelopmental disorders. Over the last few years, they’ve successfully steered their first drug (Trofinetide) into Phase 3 clinical trials (the last stage before approval) for the treatment of Rett syndrome. The final …
Centre of Excellence
FAST Australia are committed to funding and establishing an Angelman syndrome Centre of Excellence to deliver a uniform standard of care across Australia and create infrastructure for clinical trials.
GeneTx and Ultragenyx Announce Positive Interim Phase 1/2 Data
“So far we are seeing rapid improvements in multiple areas, including some kids doing things they’ve never done before, and I don’t believe this rate of progress in development skills has been seen before in Angelman syndrome,” commented Elizabeth M. Berry-Kravis, M.D. investigator in the GTX-102 clinical study.
Angelman syndrome biobank
The first biobank in Australia aiming to improve research and treatments into rare genetic diseases caused by changes to genes on chromosome 15, including Prader-Willi Syndrome and Angelman Syndrome, will be established at the Murdoch Children’s Research Institute (MCRI).
Roche Clinical trial
Roche and Genentech (the US member of the Roche group) have recruited the first patient in their Phase 1 clinical trial named "Tangelo" that is targeting AS with an oligonucleotide.
News & Media
Australian National Rugby League (NRL) identities Damien Cook, Iosia Soliola, Sam Perrett and Curtis Rona have been using their public profiles to increase awareness into Angelman syndrome.More media
The Global Angelman Syndrome Registry is creating new opportunities, insight and understanding into Angelman syndrome, providing an invaluable tool for facilitating research.Learn More
This beautiful video is one of a series produced to illustrate common features of Angelman syndrome and highlights individuality amongst those who have been diagnosed.Watch More
About the Foundation
The Foundation for Angelman Syndrome Therapeutics Australia (or FAST Australia) is an organisation of families and professionals dedicated to assisting individuals living with Angelman syndrome to realise their full potential and quality of life through funding research, education and advocacy. Our focus is treatments that will improve the symptoms of Angelman syndrome and ultimately research that will provide a cure.